Core Insights - The article emphasizes the continuous improvement of drug safety regulation and the support for the biopharmaceutical industry in the Luwest New Area [1] Group 1: Regulatory Enhancements - The Luwest New Area's Comprehensive Administrative Law Enforcement Bureau has focused on problem-oriented and result-oriented approaches to strengthen drug regulation capabilities [1] - A "Clear Source Action" was conducted to identify over 10 types of illegal activities, involving 1,600 law enforcement personnel and inspecting 463 businesses [4] - The "Code for Reassurance" platform achieved a 100% entry rate, with 77 adverse reaction reports completed, ensuring traceability of drug sources and destinations [4] Group 2: Industry Support - Key projects such as the expansion of Buchang Weixin and Danhong series are being completed, with 11 new pharmaceutical projects signed, totaling an investment of 7.51 billion [6] - The drug retail chain rate reached 86%, and 100% coverage of inspections for 149 online pharmaceutical companies was achieved [9] Group 3: Future Directions - The next steps include strengthening regulatory compliance, enhancing regulatory service capabilities, engaging the public in social governance, and continuously supporting high-quality development of the pharmaceutical industry [10]